Buy Thymosin alpha 1.5mg + bacteriostatic water 3ml
€29.84
Thymosin Alpha-1, 1.5 mg, with 3 mL bacteriostatic water, is a synthetic 28-residue peptide format for analytical and in vitro laboratory research. Pharma Research .eu provides documented EU supply subject to lot-specific purity and identity verification.
Buy Thymosin Alpha-1, 1.5 mg + Bacteriostatic Water, 3 mL, for Advanced Laboratory Research in Europe
Thymosin Alpha-1 is a synthetic, N-terminally acetylated 28-residue peptide used as a laboratory reagent in peptide analytics, immune-signalling models and controlled in vitro investigations. The commonly reported sequence is Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN, with molecular formula C₁₂₉H₂₁₅N₃₃O₅₅ and an average molecular mass of approximately 3,108.3 Da. Pharma Research .eu presents this 1.5 mg lyophilised format with 3 mL of bacteriostatic water for qualified European laboratories requiring documented peptide materials.downloads.regulations+2
Uncompromising Purity and Analytical Characterisation
The product should be defined as synthetic Thymosin Alpha-1, abbreviated Tα1, with N-terminal acetylation explicitly stated. The sequence commonly reported for the 28-residue peptide is:
Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH
The appropriate procurement target is ≥99.0% purity by RP-HPLC, subject to confirmation by the batch-specific certificate of analysis. Several research references report Tα1 as a ≥99% HPLC peptide, but a catalogue claim should not replace review of the actual chromatogram and release documentation.americanpeptides+1
The CoA should identify the peptide using several complementary attributes:
-
RP-HPLC purity percentage, chromatographic method and representative chromatogram.
-
LC-MS, ESI-MS or high-resolution MS identity confirmation.
-
Sequence designation and N-terminal acetylation status.
-
Molecular mass or principal molecular-ion assignment.
-
Appearance of the lyophilised material.
-
Residual solvent results from synthesis and purification.
-
Water or residual-moisture content, where measured.
-
Counter-ion and salt-form information.
-
Elemental-impurity or heavy-metal results where included in the quality programme.
-
Lot number, manufacture date, retest date and storage conditions.
The free-peptide molecular formula is generally given as C₁₂₉H₂₁₅N₃₃O₅₅, with reported average molecular mass around 3,108.3 g/mol. Acetate-associated or hydrated material may be reported differently, so the CoA should distinguish the nominal peptide composition from the supplied salt or formulation. A regulatory chemistry reference also lists acetate-associated reporting for Tα1 bulk drug substance, reinforcing the need to verify the exact material form.downloads.regulations+1
Thymosin Alpha-1 is typically supplied as a white to off-white lyophilised powder. Visual inspection is useful for identifying gross abnormalities but cannot establish purity or identity. Release testing should combine visual examination with chromatographic purity and mass-spectral confirmation. Because the molecule is a long, highly polar peptide, synthesis-related deletion sequences, oxidation products, deamidation products and truncated species may affect analytical performance.
Purity is particularly important for reproducible peptide-signalling experiments. Additional peptide-related peaks can alter the effective composition of a test solution, complicate dose-response interpretation, interfere with LC-MS quantification and reduce comparability between research groups. Industrial or non-characterised peptide material may lack the sequence confirmation, impurity profile and traceability required for publishable laboratory work.
The accompanying bacteriostatic water is a separate aqueous reagent and should have its own label, expiry date and documentation. Its preservative composition may influence chromatographic background, adsorption, cell viability or assay results. It should therefore not be treated as a chemically neutral solvent without method-specific verification.
Principal Laboratory Applications and Research Methodologies
Thymosin Alpha-1 is suitable for controlled laboratory research involving synthetic-peptide characterisation, analytical method development and in vitro immune-signalling models. All applications should be conducted by qualified personnel within an appropriately governed university, CRO, pharmaceutical R&D or analytical institution.
RP-HPLC and LC-MS method development. Tα1 can be used as a defined long-peptide analyte for retention-time assessment, peak integration, mass-spectral identity confirmation and stability-indicating method development. Analytical teams may assess the effects of mobile-phase composition, column chemistry, temperature and sample preparation on peptide recovery and resolution.
Peptide impurity and degradation studies. Researchers can examine potential degradation pathways under controlled temperature, light, pH, oxidation and freeze–thaw conditions. Relevant observations may include new chromatographic peaks, changes in intact-mass signal and altered recovery from assay matrices. The method should distinguish degradation from adsorption, precipitation or instrumental carryover.
In vitro immune-signalling investigations. Tα1 may be included as a defined peptide reagent in cell-free or cellular research models examining innate immune signalling, cytokine-associated responses or peptide–receptor interactions. Such experiments require validated controls, appropriate matrix blanks, vehicle controls and confirmation that the chosen solvent and bacteriostatic-water formulation do not independently influence the read-out.
Reference-material and system-suitability work. A characterised lot may support instrument qualification, retention-time comparison, sample-preparation assessment and inter-run monitoring. Unless formally certified under an applicable reference-material standard, it should be described as a research reference or analytical reagent rather than a certified reference material.
The 1.5 mg quantity corresponds to a nominal mass of approximately 0.483 µmol using the commonly reported average molecular mass of 3,108.3 g/mol. If the entire nominal quantity were dissolved into 3 mL, the theoretical concentration would be approximately 0.5 mg/mL, or about 0.161 mM, before correction for purity, salt form, water content and final volume. This is a laboratory formulation calculation only and must be checked against the actual CoA.
The 3 mL bacteriostatic-water presentation should be assessed for compatibility with the intended assay. For high-sensitivity LC-MS, a preservative-containing aqueous solution may require a separate solvent blank and matrix-effect evaluation. For cell-based work, the preservative and osmolality should be assessed independently.
Compound Stability, Optimal Storage, and Safe Handling Protocols
Thymosin Alpha-1 should remain in its sealed lyophilised form until required for a validated laboratory procedure. Research literature commonly recommends low-temperature storage and avoidance of repeated freeze–thaw cycles. However, published stability statements can vary substantially in their temperature and time claims, so the lot-specific CoA and supplier stability data should take precedence.pmc.ncbi.nlm.nih+1
Recommended controls include:
-
Store the unopened lyophilised vial at approximately −20°C unless the CoA specifies otherwise.
-
Consider −80°C for extended archival storage when supported by the laboratory stability programme.
-
Keep the vial dry, tightly closed and protected from direct light.
-
Allow a sealed vial to reach room temperature before opening to reduce condensation.
-
Use low-binding containers for prepared solutions where adsorption is a concern.
-
Prepare aliquots when repeated access would expose the material to moisture or contamination.
-
Store short-term aqueous solutions at 2–8°C only when validated for the intended assay.
-
Avoid repeated freeze–thaw cycles.
-
Record reconstitution date, solvent, concentration, operator and storage history.
The lyophilised powder is generally more stable than a prepared aqueous solution. Tα1 is an acidic peptide and may show altered recovery or chromatographic behaviour depending on pH, ionic strength and surface interactions. Research teams should validate the selected buffer or aqueous medium rather than assuming that bacteriostatic water is optimal for every method.
Reconstitution should be performed using a controlled laboratory procedure. Add the aqueous reagent slowly, allow the powder to wet, and mix gently to minimise foaming and adsorption. Do not vigorously vortex unless the method has demonstrated that the action does not promote aggregation or physical loss. Where the material will be used in a sensitive in vitro model, document the final pH, concentration and exposure time.
Handling should follow the current SDS and institutional chemical-risk assessment. Appropriate precautions generally include a certified fume hood or suitable local containment, nitrile gloves, protective eyewear and a laboratory coat. Avoid creating aerosols and prevent contact with skin, eyes and laboratory surfaces. Waste should be handled according to the institution’s chemical and laboratory-waste procedures.
Technical Specifications and Molecular Attributes
| Attribute | Specification |
|---|---|
| Product | Thymosin Alpha-1, 1.5 mg, supplied with 3 mL bacteriostatic water |
| Common abbreviation | Tα1 or TA1 |
| Sequence | Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN-OH |
| Residue count | 28 amino acids |
| IUPAC name | Full systematic peptide naming is impractical for routine procurement; use the sequence designation and lot-specific CoA |
| CAS Registry Number | 62304-98-7 is widely reported; verify the exact salt or acetate form on the CoA |
| Molecular formula | C₁₂₉H₂₁₅N₃₃O₅₅ |
| Average molecular mass | Approximately 3,108.3 g/mol |
| Monoisotopic mass | Approximately 3,106.50 Da for the stated neutral composition; confirm the supplied form |
| Physical state and colour | Lyophilised white to off-white powder |
| Solubility profile | Aqueous reconstitution may be feasible; solvent and buffer compatibility require assay-specific validation |
| Typical purity | Proposed target ≥99.0% by RP-HPLC; verify the actual lot-specific result |
| Identity testing | LC-MS, ESI-MS or high-resolution MS |
| Companion reagent | 3 mL bacteriostatic water |
| Long-term storage | Typically −20°C, protected from light and moisture; follow the CoA |
The reported formula, sequence and molecular mass are consistent across multiple chemistry and research references. CAS information should still be checked against the vendor’s documentation because catalogue records may differ by salt, hydrate or product presentation.americanpeptides+2
Pharma Research .eu: Your Premier EU Vendor for High-Purity Reagents
Pharma Research .eu can present this Tα1 format as a documented European laboratory reagent for analytical chemists, biochemists, pharmacologists and laboratory managers requiring a traceable synthetic peptide. The product file should include a batch-specific CoA, SDS, sequence designation, purity method, identity result, storage information and documentation for the bacteriostatic-water component.
Any claim that Pharma Research .eu operates an ISO 9001-certified quality-management system should be supported by a current certificate stating the issuing body, scope and validity. Claims concerning temperature-controlled logistics across EU member states should likewise be verified for each destination, carrier route and handling requirement.
A quality-focused supplier should be able to discuss:
-
N-terminal acetylation and the 28-residue sequence.
-
Free-peptide versus acetate-associated molecular mass.
-
RP-HPLC purity and LC-MS identity testing.
-
Residual solvents, water content and elemental-impurity reporting.
-
Packaging configuration and container-closure integrity.
-
Compatibility of bacteriostatic water with analytical and cellular workflows.
-
Storage, transport and reconstitution documentation.
Pharma Research .eu should therefore be described as a potential European source for research-grade Thymosin Alpha-1, while all vendor-specific claims must remain conditional on current certificates and lot records. The material is intended strictly for controlled laboratory research and analytical use by qualified personnel under applicable institutional procedures.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.


Reviews
There are no reviews yet.